HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Discover how the WHO's new guidelines on lenacapavir could revolutionise HIV prevention, offering a long-acting alternative to daily pills and addressing the needs of key populations.

Whitman-Walker Health highlights the importance of PrEP in HIV prevention and encourages collective action to increase access ...

Global health leaders and advocates challenged attendees of IAS to support the work of the partnerships that are creating patient-focused innovations for HIV prevention and treatment.

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

From the first reported case of AIDS to the present, what is the history of HIV-AIDS and are there parallels to the COVID-19 pandemic?

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

According to a phase 1 trial, the experimental HIVconsvX vaccine is safe and immunogenic among sub-Saharan African participants who bear the highest burden of HIV-1.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035.

Researchers have identified a never-before-seen mechanism that enables HIV-1 to evade the body's natural defenses and use it to support its survival and replication. The 'loophole' is a biological ...

A patient with a 33-year history of HIV-1 infection who underwent stem-cell transplantation for the treatment of acute myelogenous leukemia remained HIV-1 free nearly 5 years later.